3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Not yet recruiting
3
Unknown
2
Recruiting
2
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Melanoma
3
Carcinoma, Non-Small-Cell Lung
3
Triple Negative Breast Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Carcinoma, Renal Cell
2
Bites and Stings
2
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Pancreatic Neoplasms
1
Oligoprogressive
1
Neoplasms
1
Lung Neoplasms
1
Liver Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Trastuzumab
78
Capecitabine
59
Cyclophosphamide
54
Paclitaxel
52
Docetaxel
50
Letrozole
44
Fulvestrant
43
Lapatinib
34
Doxorubicin
31
Carboplatin
31
Vinorelbine
30
Bevacizumab
29
Anastrozole
28
pembrolizumab
26
exemestane
24
Tamoxifen
23
Gemcitabine
22
Radiotherapy
21
Albumin-Bound Paclitaxel
19
Taxes
17
Everolimus
17
Epirubicin
15
pertuzumab
13
Ado-Trastuzumab Emtansine
13
130-nm albumin-bound paclitaxel
13
palbociclib
12
Magnetic Resonance Spectroscopy
12
liposomal doxorubicin
11
atezolizumab
11
Filgrastim
11
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Breast Neoplasms
×
Immune Checkpoint Inhibitors
×
Clear all
NCT05716295
2024-05-08
ORCHID-1
Medikine, Inc.
Phase 1/2
Terminated
26 enrolled